drugset
drugset / Trial / NCT02171650

BIBW 2992 in Patients With Advanced Solid Tumors

NCT02171650 ↗

Phase 1 Completed 7 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The primary objective was to collect safety data for BIBW 2992.

Timeline

Start
2004-12-01
Primary completion
2006-05-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule — Oral

Indications

neoplasm